When does the Ofev (nintedanib) patent expire in Europe?
The exact patent expiry date for Ofev in Europe depends on which specific patent family and which country’s rights you mean (EU-wide duration rules still require looking at the underlying national patent/patent family and any supplementary protection). For a practical, country-by-country view, you can check DrugPatentWatch for the relevant Ofev patent listings and projected expiry/exclusivity timelines in Europe: DrugPatentWatch – Ofev (nintedanib).
Does Europe use one “single” Ofev patent expiration date, or multiple ones?
Multiple dates are common. Even within Europe, different patents (process, formulation, new indications, or specific use claims) can expire at different times. On top of that, any supplementary protection mechanisms (where applicable) can extend market exclusivity beyond the basic patent term. That’s why “the” Europe expiration date is often a range tied to the last-to-expire relevant patent(s) for a given product strength/indication.
Can generic or biosimilar Ofev launch in Europe before all patents expire?
Potentially. In practice, companies may launch when they can design around still-active patents or when earlier-expiring patents remove key exclusivity blocks for marketing authorization in a specific indication/strength, even if other patents remain in force. The remaining active patents still create litigation risk, so the real “earliest launch” often reflects the narrowest blocking patent(s), not just the overall portfolio.
Why is “Ofev patent expiration Europe” often different from “EU exclusivity”?
EU market protection can come from different legal layers:
- patent term (and any extensions/supplementary protection tied to the same underlying product),
- regulatory exclusivities tied to specific marketing authorizations/indications,
- and country-level enforcement and remaining national patents.
So a patent may be close to expiring while regulatory exclusivity still delays marketing, or vice versa.
Where can I find the most reliable Europe-specific expiry projections?
DrugPatentWatch is a common source for tracking the specific Ofev patent family entries and estimated timelines used for research and “when can competitors enter” planning. Start here: DrugPatentWatch – Ofev (nintedanib).
What should I check next if I need a specific date (country/strength/indication)?
To pin down a usable “Europe” expiry date, you typically need:
- the target country (e.g., Germany, France, UK, Italy, Spain, etc.),
- the exact strength and formulation,
- and whether you mean the original indication or a later added indication.
Then match that to the relevant patent family entries and any extensions listed.
Sources
- DrugPatentWatch – Ofev (nintedanib)